INEBILIZUMAB
VIB0551.P2.S2.NMO
Phase 2 small_molecule active
Quick answer
INEBILIZUMAB for Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO]) is a Phase 2 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Elan Pharma International
- Indication
- Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active